Trial Profile
Pilot Study of Mepolizumab in Episodic Angioedema With Eosinophilia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Angioedema; Eosinophilia
- Focus Therapeutic Use
- 09 Nov 2023 Results assessing the role of IL-5-driven eosinophilia in the clinical manifestations of EAE published in the Journal of Allergy and Clinical Immunology
- 27 Feb 2023 Results presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 02 Nov 2022 Status changed from recruiting to completed.